Saturday 17 October 2026
Export QSI’s income statement to Excel — free account
Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 41.8%, EPS grew 31.3% and free cash flow grew 9.75%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.12
0.19
−14.50%
Follow QSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
120.77 | 90.00 | 89.30 | 92.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.51) | (6.50) | (13.31) | (9.21) | |
P/B ratio |
1.08 | 0.83 | 0.99 | 1.25 | |
Price to Tangible BV |
1.08 | 0.83 | 0.99 | 1.25 | |
EV/Sales |
51.15 | 21.24 | 22.43 | 21.69 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.89) | (0.42) | (0.58) | (0.68) | |
EV/FCF |
(0.88) | (0.41) | (0.56) | (0.65) | |
Quick Ratio |
9.36 | 11.91 | 7.30 | 10.44 | |
Current Ratio |
9.97 | 12.60 | 7.64 | 10.75 | |
Net Debt/EBITDA |
4.45 | 5.37 | 7.58 | 5.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.78 | 1.18 | 0.93 | 0.90 | |
Capex/Depreciation |
(0.15) | (0.83) | (0.04) | 0.88 | |
Research and Development Expense of Revenue |
4,600.00% | 5,615.12% | 2,427.05% | 2,515.04% | |
Selling, General and Administrative Expense of Revenue |
2,900.29% | 3,736.43% | 2,277.16% | 1,939.67% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
886.63% | 994.19% | 596.01% | 512.14% | |
Graham Net Nets |
0.55 | 0.73 | 0.69 | 0.72 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(51.69%) | (66.23%) | (47.27%) | (47.52%) | |
Free Cash Flow Yield |
(48.33%) | (57.41%) | (44.70%) | (35.70%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.08) | (0.12) | (0.08) | (0.15) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.12) | (0.08) | (0.16) | |
Cash per Share |
0.51 | 0.59 | 0.82 | 1.08 | |
Shareholders Equity per Share |
0.83 | 0.93 | 1.11 | 1.12 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.83 | 0.93 | 1.11 | 1.12 | |
Free Cash Flow |
(18.52) | (25.92) | (16.33) | (32.92) | |
Working Capital |
107.14 | 124.26 | 152.84 | 215.84 | |
Capital Expenditures |
(0.08) | (0.28) | 0.02 | (0.90) | |
Net Current Asset Value |
105.71 | 122.36 | 150.48 | 213.02 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.23 | 1.08 | (0.04) | 1.63 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.81 | 0.62 | 3.27 | 3.21 | |
Average Payables |
1.91 | 1.84 | 1.78 | 1.75 | |
Average Inventory |
2.97 | 3.31 | 3.63 | 3.80 | |
Average Assets |
223.99 | 242.29 | 246.74 | 248.29 | |
Average Common Equity |
200.59 | 223.83 | 217.82 | 222.84 |
Columns are period end dates